tradingkey.logo

Bridgebio Pharma Plans To Submit NDA For BBP-418 To FDA In H1 2026

ReutersMar 11, 2026 6:07 PM

- BridgeBio Pharma Inc BBIO.O:

  • BBP-418 DEMONSTRATES CONSISTENT EFFICACY AND FAVORABLE SAFETY PROFILE IN PHASE 3 FORTIFY INTERIM ANALYSIS IN LGMD2I/R9

  • BRIDGEBIO PHARMA INC - TO SUBMIT NDA FOR BBP-418 TO FDA IN H1 2026

  • BRIDGEBIO PHARMA INC - BBP-418 WELL TOLERATED WITH SAFETY PROFILE COMPARABLE TO PLACEBO

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

KeyAI